Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) shares were up 18.7% during mid-day trading on Thursday . The company traded as high as C$2.16 and last traded at C$1.97. Approximately 198,919 shares changed hands during trading, an increase of 89% from the average daily volume of 105,118 shares. The stock had previously closed at C$1.66.
Medicenna Therapeutics Stock Performance
The company has a quick ratio of 4.65, a current ratio of 2.51 and a debt-to-equity ratio of 0.06. The firm has a 50 day moving average price of C$2.03 and a 200 day moving average price of C$2.10. The stock has a market cap of C$149.80 million, a PE ratio of -5.16 and a beta of 1.21.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
Further Reading
- Five stocks we like better than Medicenna Therapeutics
- 3 Monster Growth Stocks to Buy Now
- Fast-Growing Companies That Are Still Undervalued
- How to Find Undervalued Stocks
- Top Cybersecurity Stock Picks for 2025
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Archer or Joby: Which Aviation Company Might Rise Fastest?
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
